Australian Pharmaceuticals & Biotech Big Green Snowflakes

EZZ Life Science Holdings

Market Cap: AU$103.3m

Engages in formulation, production, marketing, and sale of the health and wellbeing products in Australia, New Zealand, Mainland China, and South-East Asia.

CSL

Market Cap: AU$94.0b

Engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally.

Medical Developments International

Market Cap: AU$76.6m

Manufactures and distributes emergency medical solutions in Australia, Asia, Europe, the United States, and internationally.

Alterity Therapeutics

Market Cap: AU$103.3m

Engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia.

Clinuvel Pharmaceuticals

Market Cap: AU$566.4m

A biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally.

Vita Life Sciences

Market Cap: AU$136.3m

A healthcare company, engages in formulating, packaging, distributing, and selling vitamins and supplements in Australia, Singapore, Malaysia, Thailand, Vietnam, Indonesia, and China.

Neuren Pharmaceuticals

Market Cap: AU$2.4b

A biopharmaceutical company, develops drugs for the treatment of neurological disorders.

Trajan Group Holdings

Market Cap: AU$112.1m

Develops, manufactures, and sells analytical and life science products and devices in Malaysia, Japan, Australia, New Zealand, the United States, Europe, the Middle East, Africa, and India.

Botanix Pharmaceuticals

Market Cap: AU$304.0m

Operates as a commercial dermatology company in Australia and the United States.

Cynata Therapeutics

Market Cap: AU$52.2m

Engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia.

Acrux

Market Cap: AU$5.7m

Develops and commercializes generic and topically applied pharmaceutical products in Australia, Europe, the United States, and internationally.

Percheron Therapeutics

Market Cap: AU$10.9m

Engages in the research and development of novel antisense pharmaceuticals for cancer and rare diseases in Australia.

Telix Pharmaceuticals

Market Cap: AU$5.0b

A commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals.

Immutep

Market Cap: AU$374.3m

A biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia.

Syntara

Market Cap: AU$40.8m

Operates as a clinical-stage drug development company that targets extracellular matrix dysfunction through amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis in Australia.

Mesoblast

Market Cap: AU$3.1b

Engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland.

Vitura Health

Market Cap: AU$42.4m

Engages in the sale and distribution of medicinal cannabis products in Australia.

PYC Therapeutics

Market Cap: AU$577.4m

A drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia.

LTR Pharma

Market Cap: AU$119.4m

A clinical-stage pharmaceutical company, engages in the research and development of intranasal spray for the treatment erectile dysfunction (ED) in Australia.

Little Green Pharma

Market Cap: AU$38.2m

Engages in the cultivation, production, and distribution of medicinal cannabis products in Australia and internationally.

Avecho Biotechnology

Market Cap: AU$20.6m

A biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, the Americas, and India.

Radiopharm Theranostics

Market Cap: AU$68.6m

A clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs.

Genetic Signatures

Market Cap: AU$61.3m

Operates as a molecular diagnostic company in Australia, the Asia Pacific, Europe, the Middle East, Asia, and the Americas.

Prescient Therapeutics

Market Cap: AU$43.6m

A clinical stage oncology company, develops drugs for the treatment of various cancers in Australia.

Biotron

Market Cap: AU$4.0m

A biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia.

Actinogen Medical

Market Cap: AU$101.6m

A biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia.

Aroa Biosurgery

Market Cap: AU$239.8m

Develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally.

Mayne Pharma Group

Market Cap: AU$419.2m

A specialty pharmaceutical company, focuses on the commercialization of women’s health and dermatology pharmaceuticals in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally.

Vitrafy Life Sciences

Market Cap: AU$79.8m

Engages in the research, development, and commercialization of cryopreservation solutions in Australia.

Imugene

Market Cap: AU$79.9m

A clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia.

Island Pharmaceuticals

Market Cap: AU$104.0m

A drug repurposing company, focuses on the development of antiviral therapeutics for antiviral therapeutics in Australia and the United States of America.

Immuron

Market Cap: AU$20.4m

A biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada.

Paradigm Biopharmaceuticals

Market Cap: AU$123.5m

Engages in the research and development of therapeutic products for human use in Australia.

Invion

Market Cap: AU$9.4m

A clinical-stage life sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in Australia.

Invex Therapeutics

Market Cap: AU$12.0m

A biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia.

Argenica Therapeutics

Market Cap: AU$34.7m

A biotechnology company, engages in the research and development of neuroprotective therapeutic drugs in Australia.